Ceritinib in anaplastic lymphoma kinase-positive nonsmall cell lung cancer among patients who were previously exposed to crizotinib: Experience from the Indian subcontinent.
Sign Up to like & getrecommendations! Published in 2017 at "Indian journal of cancer"
DOI: 10.4103/ijc.ijc_186_17
Abstract: Ceritinib is a novel ALK inhibitor approved for advanced stage NSCLC with ALK gene rearrangement, progressed and/or intolerant to crizotinib. 13 patients were included in our study who received ceritinib. Majority of them were women… read more here.
Keywords: lymphoma kinase; anaplastic lymphoma; crizotinib; ceritinib ... See more keywords